The price lists may still be confusing to consumers, though, because standard rates are like list prices and don’t reflect what insurers and government programs pay. “Given the inherent complexity of hospital billing, making prices easy to understand is clearly a lot easier said than done,” Shawn Gremminger, of Families USA. https://khn.org/morning-breakout/hospitals-to-be-required-to-post-prices-online-as-part-of-cms-push-to-increase-transparency/
There is a growing trend in big pharma to talk up the potential for digital technology to revolutionise operations and Novartis is one of the companies that is most actively announcing steps to explore this possibility.
In August of last year, the company announced a new position, Chief Digital Officer, and the man to take the position, in Bertrand Bodson.
read more http://www.pharmafile.com/news/517158/novartis-forges-forward-digital-pharma-focalview-app
The integration of roles in the health system should theoretically result in better coordination of care and outcomes for patients. … http://www.pm360online.com/how-pharma-can-help-patients-feel-less-overwhelmed-when-dealing-with-payers/
Sandoz, a division of Novartis, and Pear Therapeutics have agreed to jointly commercialize and continue development of novel prescription digital therapeutics designed to treat disease and improve clinical outcomes for patients. http://drugdiscovery.pharmaceutical-business-review.com/news/sandoz-pear-to-develop-digital-therapeutics-for-substance-use-disorder-190418-6121611
Novartis just bet close to $9 billion on the future of gene therapy, a boost for a field that hasn’t yet seen commercial success. In the same week, GlaxoSmithKline, which has one of the few gene therapies on the market and has struggled to sell it, is asking out. The British pharma giant will send […] https://www.xconomy.com/boston/2018/04/12/as-novartis-buys-into-gene-therapy-gsk-bows-out-with-orchard-deal/
AstraZeneca has licensed a NASH candidate from Ionis. The Big Pharma is paying $30 million upfront to pick up the rights to the program and take it into the clinic. https://www.fiercebiotech.com/biotech/astrazeneca-licenses-ionis-clinical-phase-antisense-nash-drug
The R&D playbook is evolving as the industry looks to break down the silos between clinical and commercial operations â bringing commercial voices to the earliest phases of asset development. https://www.outsourcing-pharma.com/Article/2018/03/13/Commercial-Trends-Forecast-R-D-is-transforming-into-R-D-C
Novartis is expanding its strategic alliance with Science 37 and has committed to conducting up to 10 new clinical trials â blending both virtual and traditional models â over the next three years. https://www.outsourcing-pharma.com/Article/2018/03/07/Novartis-scaling-site-less-trials-through-expanded-Science-37-alliance
Clinical Informatics News Contributed Commentary In January 2017, there were 4,003 pharmaceutical companies with nearly 15,000 drugs in the pipeline. Yet only 1 in 5 drugs actually make it to market. Technology inherently aims to streamline processes, eliminate manual effort and create efficiencies, but is technology still doing this for clinical research?